Heart Transplantation Under Cyclosporine or Tacrolimus Combined With Mycophenolate Mofetil or Everolimus

Transplantation Proceedings

Volumn 40, Issue 8, 2008, Pages 2607-2608

  Wang, S S ^a   Chou, N K ^a   Chi, N H ^a   Wu, I H ^a   Chen, Y S ^a   Yu, H Y ^a   Huang, S C ^a   Wang, C H ^a   Ko, W J ^a   Tsao, C I ^a   Sun, C D ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYCLOSPORIN; EVEROLIMUS; HEPATITIS B SURFACE ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CLINICAL TRIAL; COLD ISCHEMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORGAN DONOR; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SURVIVAL RATE; THERAPY; TREATMENT FAILURE; VIRUS INFECTION;

ADULT; CARDIOMYOPATHY, DILATED; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; MYOCARDIAL ISCHEMIA; PATIENT SELECTION; SIROLIMUS; SURVIVAL ANALYSIS; SURVIVORS; TACROLIMUS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 53149101690     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.08.072     Document Type: Article

References (7)

1. Wang C.H., Ko W.J., Chou N.K., et al. Efficacy and safety of tacrolimus versus cyclosporine microemulsion in primary cardiac transplant recipients: 6-month results in Taiwan. Transplant Proc 36 (2004) 2384
2. Wang C.H., Ko W.J., Chou N.K., et al. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. Transplant Proc 36 (2004) 2386
3. Wang S.S., Chou N.K., Chi N.H., et al. Simultaneous heart and kidney transplantation for combined cardiac and renal failure. Transplant Proc 38 (2006) 2135
4. Wang S.S., Chou N.K., Ko W.J., et al. Effect of plasmapheresis for acute humoral rejection after heart transplantation. Transplant Proc 38 (2006) 3692
5. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 349 (2003) 847
6. Keogh A., Richardson M., Ruygrok P., et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. Circulation 110 (2004) 2694
7. Eisen H., and Yang X. The impact of proliferation signal inhibitors on the healthcare burden of major adverse cardiac events following heart transplantation. Transplantation 82 (2006) S13